Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil.

IF 3.4 2区医学 Q3 IMMUNOLOGY

AIDS Pub Date : 2024-07-15 Epub Date: 2024-06-27 DOI:10.1097/QAD.0000000000003916

Lucy Campbell, Birgit Barbini, Ben Cromarty, Lisa Hamzah, Deborah Williams, Alan Winston, Frank A Post

引用次数: 0

Abstract

Twenty-eight individuals who experienced proximal renal tubulopathy (PRT, Fanconi syndrome) while receiving tenofovir disoproxil initiated tenofovir alafenamide (TAF) and were followed for 5 years. None developed recurrent PRT or experienced significant changes in estimated glomerular filtration rate (by creatinine or cystatin-C), albuminuria, proteinuria, retinol-binding proteinuria, fractional excretion of phosphate, alkaline phosphatase, or bone mineral density at the lumbar spine. These data suggest that TAF is a well tolerated treatment option for individuals vulnerable to developing PRT.

查看原文本刊更多论文

服用替诺福韦酯后出现近端肾小管病变的艾滋病毒感染者服用替诺福韦-阿拉非酰胺的安全性。

有 28 人在接受替诺福韦酯治疗期间出现近端肾小管病变（PRT，范可尼综合征），随后开始接受替诺福韦阿拉非酰胺（TAF）治疗，并随访 5 年。没有人复发PRT，估计肾小球滤过率（肌酐或胱抑素-C）、白蛋白尿、蛋白尿、视黄醇结合蛋白尿、磷酸盐部分排泄量、碱性磷酸酶或腰椎骨矿物质密度也没有发生显著变化。这些数据表明，对于易患 PRT 的人来说，TAF 是一种耐受性良好的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS 医学-病毒学

CiteScore

5.90

自引率

5.30%

发文量

478

审稿时长

3 months

期刊介绍： Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.